Get Started. It's Free
or sign up with your email address
Rocket clouds
Cancer by Mind Map: Cancer

1. Targeted Therapies

1.1. Kinase Inhibitors

1.1.1. Tyrosine Kinase Inhibitors

1.1.1.1. Transmembrane receptors

1.1.1.1.1. EGFR targeted KI

1.1.1.1.2. HER2 targeted KI

1.1.1.1.3. cMET targeted KI

1.1.1.1.4. VEGF

1.1.1.2. Intracellular receptors

1.1.1.2.1. Brc-Abl KI

1.1.1.2.2. ALK targetted KI

1.1.2. Inhibit MAPK pathway

1.1.2.1. BRAF V-600 I

1.1.2.1.1. Dabrafenib

1.1.2.2. MEK1 and MEK2 I

1.1.2.2.1. Trametinib

1.1.3. Inhibit P13K pathway

1.1.3.1. Idealisib

1.1.3.2. Acalabrutinib

1.1.3.3. Rapalogs

1.1.3.3.1. Temsiroliumus

1.1.3.3.2. Everoliumus

1.1.3.3.3. Sirolimus

1.2. Anti-Endocrine Therapies

1.2.1. AR antagonists

1.2.1.1. Enzalutamide

1.2.1.2. Apalutamide

1.2.2. Drugs that prevent DHT production

1.2.2.1. CYP17 Inhibitor

1.2.2.1.1. Abiraterone

1.2.2.2. 5 alpha reductase Inhibitors

1.2.2.2.1. Finasteride

1.2.2.2.2. Dutasteride

1.2.3. GnRH antagonist

1.2.3.1. Abralix

1.2.3.2. Degarelix

1.2.4. GnRH analogs

1.2.4.1. Leuprolide acetate

1.2.4.2. Goselerin

1.2.5. Anti Estrogen therapy

1.2.5.1. SERM

1.2.5.1.1. Tamoxifen

1.2.5.1.2. Raloxifene

1.2.5.2. SERD

1.2.5.2.1. Fulvestrant

1.2.5.3. Aromatase Inhibitors

1.2.5.3.1. non steroidial

1.2.5.3.2. steroidal

1.3. Immunology

1.3.1. monoclonal antibodies

1.3.1.1. Her2

1.3.1.1.1. Trastuzumab

1.3.1.1.2. Pertuzumab

1.3.1.2. EGFR

1.3.1.2.1. Cetuximab

1.3.1.2.2. Panitumumab

1.3.1.3. CD20

1.3.1.3.1. Ofatumumab

1.3.1.3.2. Rituximab

1.3.1.4. VEGF

1.3.1.4.1. Bevacizumab

1.3.1.4.2. Ramucirumab

1.3.1.5. T cells

1.3.1.5.1. Ipilimumab

1.3.1.5.2. PD

1.3.2. Antibody drug conjugates

1.3.2.1. Ado- Trastuzumab Emtansine

1.3.2.2. Brentuximab

1.3.3. Bispecific Antibodies

1.3.3.1. Blinatumomab

1.3.4. Cell therapy

1.3.4.1. Chimeric Antigen Receptors (CAR-T cell therapy)

1.3.4.1.1. Tisagenlecluecel

1.3.4.1.2. Sipuleucel T

1.3.5. T cell therapy

1.3.5.1. Interleukin 2

1.3.5.1.1. Aldesleukin

1.3.6. Vaccines

1.3.6.1. HPV

1.3.6.1.1. Quadrivalent HPV

1.3.6.1.2. Bivalent HPV

2. Chemotherapy

2.1. Alkylating Agents

2.1.1. Nitroureas

2.1.1.1. Carmustine

2.1.2. Alkyl Sulfonates

2.1.2.1. Busulfan

2.1.3. Procarbazine

2.1.4. monoalkylating agents

2.1.4.1. Temozolomide

2.1.5. aziridine compounds

2.1.5.1. Mustards

2.1.5.1.1. Mechlorethamine Derivatives

2.1.5.2. Mitomycin C

2.2. Drug resistance for alkylating agents and platinum agents

2.2.1. Increased expression of DNA repair enzymes

2.2.2. Increased intracellular concentration of non-protein thiols, especially glutathione !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

2.2.3. increased expression of cellular glutathione S-transferase (GST)

2.3. Platinum Agents

2.3.1. Cisplatin

2.4. Antimetabolites

2.4.1. Pyrimidine analogs

2.4.1.1. Uridine analogs

2.4.1.1.1. 5-Fluorouracil

2.4.1.2. Cytosine analogs

2.4.1.2.1. Cytosine Arabinoside

2.4.2. Purine Analogs

2.4.2.1. 6-Mercaptopurine

2.4.2.2. Adenosine Analog

2.4.2.2.1. Cladribine

2.4.2.3. Arabino Adenosine analog

2.4.2.3.1. Nelrabine

2.4.3. Antifolates

2.4.3.1. DHFR inhibitors

2.4.3.1.1. Methotrexate

2.4.4. Hydroxyurea

2.4.5. Actinomycin C

2.4.6. Asparaginase

2.5. Topoisomerase Inhibitors

2.5.1. Topoisomerase 1 Inhibitors

2.5.1.1. Camptothecins

2.5.1.2. Water Soluble Camptothecins analogs

2.5.1.2.1. Topotecan

2.5.1.2.2. Irinotecan

2.5.2. Topoisomerase II inhibitors

2.5.2.1. Anthracyclines

2.5.2.1.1. Doxorubicin

2.5.2.2. Mitoxantrone

2.5.2.3. Etoposide

2.5.2.4. Resistance

2.6. Microtubule Inhibitors

2.6.1. Destabilizers

2.6.1.1. Vinca alkaloids

2.6.1.1.1. Vincristine

2.6.2. de-polymerizing

2.6.2.1. Erubulin

2.6.3. Stabilizers

2.6.3.1. Taxanes

2.6.3.1.1. Paclitaxel

2.6.3.2. Epothilone

2.7. Inhibition of cyclin dependent kinases

2.7.1. Palbociclib

3. Extras

3.1. Bleomycin

3.2. Olaparib

3.3. Retinoids

3.3.1. Tretinoin

3.3.2. Bexarotene

3.4. Proteasome inhibitors

3.4.1. Bortezomib

3.4.2. Carfilzomib

3.4.3. Ixazomib

3.5. Sonidegib

3.6. Venetoclax

3.7. Omacetaxine

3.8. Selinexor

3.9. Posttranslational modifications that affect proteins

3.9.1. histones

3.9.1.1. Methylation

3.9.1.1.1. EZH2

3.9.1.2. Acetylation

3.9.1.2.1. HDAC I

3.9.2. DNMT

3.9.2.1. Methylation

3.9.2.1.1. Azacytidine